{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T21:35:21Z","timestamp":1771364121852,"version":"3.50.1"},"reference-count":58,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Padra Serum Alborz","award":["99\/20880"],"award-info":[{"award-number":["99\/20880"]}]}],"content-domain":{"domain":["www.plosglobalpublichealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Glob Public Health"],"abstract":"<jats:p>Snakebite envenomation is a significant public health issue in Iran, and it is crucial to have effective and easily accessible antivenom treatments. This study aimed to evaluate the non-inferiority of the SnaFab and the Razi antivenoms for treating snakebite envenomation. The study was a randomized, double-blind, multicenter, active-controlled, non-inferiority trial involving 98 snakebite victims. The patients received either the SnaFab or the Razi antivenoms, with the primary endpoint being the recovery rate within 48 hours after antivenom infusion. The secondary endpoints included adverse events over a 14-day monitoring period and total antivenom consumption. The non-inferiority margin (NIM) was set at 20 percent. The study was commenced on April 17th, 2020, and concluded on May 15th, 2021. The recovery rate was 100 percent in the SnaFab group, which was non-inferior to the Razi antivenom group (98%). The mean number of antivenom units administered was 8.95\u2009\u00b1\u20094.40 units in the SnaFab group, compared to 9.04\u2009\u00b1\u20094.49 units in the Razi group (P value: 0.92). Adverse events were reported by 10.2% of individuals in the SnaFab group and 20.4% in the Razi group (p value\u2009=\u20090.27). Muscle weakness was the most commonly reported adverse event in the Razi group (8%), while vertigo was most frequent in the SnaFab group (4%). Moreover, there were no reports of anaphylactic shock or serum sickness. In summary, this study found that SnaFab antivenom is non-inferior to Razi antivenom for treating snakebite envenomation in Iran. Overall, the incidence of adverse events was comparable between groups, with no statistically significant differences observed.<\/jats:p>","DOI":"10.1371\/journal.pgph.0004281","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T18:23:59Z","timestamp":1764008639000},"page":"e0004281","update-policy":"https:\/\/doi.org\/10.1371\/journal.pgph.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["The SnaFab versus the Razi antivenom for treatment of snakebite envenomation: A randomized, double-blind (investigator and victims), active controlled, non-inferiority clinical trial"],"prefix":"10.1371","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3817-5928","authenticated-orcid":true,"given":"Seyed Reza","family":"Mousavi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alihasan","family":"Rahmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Amini Pouya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elnaz","family":"Zabihi Eidgahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad","family":"Delirrad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamed","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Ghassemi Toussi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behnaz","family":"Hedayatjoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyyedeh Maryam","family":"Afshani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Amin","family":"Ghobadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Reza","family":"Shahidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Amirhossein","family":"Mousavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Barghbani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3659-2963","authenticated-orcid":true,"given":"Mahdi Jannati","family":"Yazdan Abad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"1","key":"pgph.0004281.ref001","doi-asserted-by":"crossref","first-page":"6160","DOI":"10.1038\/s41467-022-33627-9","article-title":"Global mortality of snakebite envenoming between 1990 and 2019","volume":"13","author":"GBD 2019 Snakebite Envenomation Collaborators","year":"2022","journal-title":"Nat Commun"},{"issue":"10430","key":"pgph.0004281.ref002","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0140-6736(23)01698-7","article-title":"Strengthening global snakebite data for WHO\u2019s goal for 2030","volume":"403","author":"H Munshi","year":"2024","journal-title":"Lancet"},{"key":"pgph.0004281.ref003","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/1471-2164-12-259","article-title":"Profiling the venom gland transcriptomes of Costa Rican snakes by 454 pyrosequencing","volume":"12","author":"J Durban","year":"2011","journal-title":"BMC Genomics"},{"issue":"9708","key":"pgph.0004281.ref004","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0140-6736(09)61754-2","article-title":"Snake bite","volume":"375","author":"DA Warrell","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"pgph.0004281.ref005","doi-asserted-by":"crossref","first-page":"9818","DOI":"10.1038\/s41598-018-28135-0","article-title":"Variability in venom composition of European viper subspecies limits the cross-effectiveness of antivenoms","volume":"8","author":"G Zanetti","year":"2018","journal-title":"Sci Rep"},{"key":"pgph.0004281.ref006","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40409-017-0127-6","article-title":"Snakebite envenomation turns again into a neglected tropical disease!","volume":"23","author":"J-P Chippaux","year":"2017","journal-title":"J Venom Anim Toxins Incl Trop Dis"},{"key":"pgph.0004281.ref007","volume-title":"Ending the neglect to attain the sustainable development goals: a road map for neglected tropical diseases 2021\u20132030","author":"World Health O","year":"2020"},{"issue":"5","key":"pgph.0004281.ref008","first-page":"515","article-title":"Snake-bites: appraisal of the global situation","volume":"76","author":"JP Chippaux","year":"1998","journal-title":"Bull World Health Organ"},{"issue":"11","key":"pgph.0004281.ref009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050218","article-title":"The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths","volume":"5","author":"A Kasturiratne","year":"2008","journal-title":"PLoS Med"},{"key":"pgph.0004281.ref010","volume-title":"Standardization WHOECoB","author":"World Health O","year":"2017"},{"key":"pgph.0004281.ref011","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.toxicon.2021.12.020","article-title":"First report of a confirmed case of Montivipera latifii (Latifi\u2019s viper) envenoming and a literature review of envenoming by Montivipera species","volume":"207","author":"H Hassanian-Moghaddam","year":"2022","journal-title":"Toxicon"},{"key":"pgph.0004281.ref012","doi-asserted-by":"crossref","first-page":"107197","DOI":"10.1016\/j.toxicon.2023.107197","article-title":"Identifying the geographic distribution pattern of venomous snakes and regions of high snakebite risk in Iran","volume":"231","author":"SM Kazemi","year":"2023","journal-title":"Toxicon"},{"key":"pgph.0004281.ref013","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.toxicon.2014.08.063","article-title":"Ten years of snakebites in Iran","volume":"90","author":"R Dehghani","year":"2014","journal-title":"Toxicon"},{"issue":"2","key":"pgph.0004281.ref014","first-page":"153","article-title":"Snakebite management in Iran: Devising a protocol","volume":"19","author":"SM Monzavi","year":"2014","journal-title":"J Res Med Sci"},{"issue":"24","key":"pgph.0004281.ref015","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1001\/jama.2012.87802","article-title":"Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement","volume":"308","author":"G Piaggio","year":"2012","journal-title":"JAMA"},{"issue":"7","key":"pgph.0004281.ref016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000767","article-title":"Randomised controlled double-blind non-inferiority trial of two antivenoms for saw-scaled or carpet viper (Echis ocellatus) envenoming in Nigeria","volume":"4","author":"IS Abubakar","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"pgph.0004281.ref017","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.toxicon.2018.05.009","article-title":"The snakebite problem and antivenom crisis from a health-economic perspective","volume":"150","author":"AG Habib","year":"2018","journal-title":"Toxicon"},{"issue":"9247","key":"pgph.0004281.ref018","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/S0140-6736(05)74319-1","article-title":"Crisis in snake antivenom supply for Africa","volume":"356","author":"RD Theakston","year":"2000","journal-title":"Lancet"},{"issue":"9","key":"pgph.0004281.ref019","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.jprot.2011.05.027","article-title":"Ending the drought: new strategies for improving the flow of affordable, effective antivenoms in Asia and Africa","volume":"74","author":"DJ Williams","year":"2011","journal-title":"J Proteomics"},{"key":"pgph.0004281.ref020","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.toxicon.2015.09.039","article-title":"European viper envenomation recorded by French poison control centers: A clinical assessment and management study","volume":"108","author":"V Jollivet","year":"2015","journal-title":"Toxicon"},{"issue":"9708","key":"pgph.0004281.ref021","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0140-6736(09)61159-4","article-title":"The Global Snake Bite Initiative: an antidote for snake bite","volume":"375","author":"D Williams","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"pgph.0004281.ref022","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4038\/sljm.v27i1.79","article-title":"Pharmacodynamics and pharmacokinetics of snake antivenom","volume":"27","author":"B Nikapitiya","year":"2018","journal-title":"SL J Med"},{"issue":"3","key":"pgph.0004281.ref023","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/bcp.12739","article-title":"Adverse reactions to snake antivenom, and their prevention and treatment","volume":"81","author":"HA de Silva","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"pgph.0004281.ref024","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3831\/KPI.2022.25.2.114","article-title":"Purification of Therapeutic Serums of Snake Anti-Venom with Caprylic Acid","volume":"25","author":"N Norouznejad","year":"2022","journal-title":"J Pharmacopuncture"},{"issue":"6","key":"pgph.0004281.ref025","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0041-0101(98)00220-7","article-title":"A randomized blinded clinical trial of two antivenoms, prepared by caprylic acid or ammonium sulphate fractionation of IgG, in Bothrops and Porthidium snake bites in Colombia: correlation between safety and biochemical characteristics of antivenoms","volume":"37","author":"R Otero","year":"1999","journal-title":"Toxicon"},{"issue":"3","key":"pgph.0004281.ref026","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0041-0101(89)90177-3","article-title":"Purification of F (ab\u2032) 2 anti-snake venom by caprylic acid: a fast method for obtaining IgG fragments with high neutralization activity, purity and yield","volume":"27","author":"M Dos Santos","year":"1989","journal-title":"Toxicon"},{"key":"pgph.0004281.ref027","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jim.2013.11.001","article-title":"Single-reagent one-step procedures for the purification of ovine IgG, F(ab\u2019)2 and Fab antivenoms by caprylic acid","volume":"402","author":"I Al-Abdulla","year":"2014","journal-title":"J Immunol Methods"},{"issue":"3","key":"pgph.0004281.ref028","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.biologicals.2004.07.001","article-title":"Assessment of the viral safety of antivenoms fractionated from equine plasma","volume":"32","author":"T Burnouf","year":"2004","journal-title":"Biologicals"},{"issue":"4","key":"pgph.0004281.ref029","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.biologicals.2007.02.004","article-title":"Partitioning and inactivation of viruses by the caprylic acid precipitation followed by a terminal pasteurization in the manufacturing process of horse immunoglobulins","volume":"35","author":"M Mpandi","year":"2007","journal-title":"Biologicals"},{"key":"pgph.0004281.ref030","volume-title":"Office of Medical P, et al. Conduct of clinical trials of medical products during the COVID-19 public health emergency: guidance for industry, investigators, and institutional review boards","author":"United States. Department of H, Human Services ib, United States F, Drug Administration ib, United States F, Drug Administration","year":"2021"},{"issue":"2","key":"pgph.0004281.ref031","doi-asserted-by":"crossref","first-page":"67","DOI":"10.5812\/atr.6445","article-title":"Incidence of snake bites in kashan, iran during an eight year period (2004-2011)","volume":"1","author":"R Dehghani","year":"2012","journal-title":"Arch Trauma Res"},{"issue":"1","key":"pgph.0004281.ref032","doi-asserted-by":"crossref","DOI":"10.32598\/ijmtfm.v15i1.45734","article-title":"A seven-year epidemiological study of snakebite cases among children and adolescents in South Khorasan, Eastern Iran","volume":"15","author":"S Shaban","year":"2025","journal-title":"International Journal of Medical Toxicology and Forensic Medicine"},{"issue":"4","key":"pgph.0004281.ref033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0012080","article-title":"Snakebite envenoming: A systematic review and meta-analysis of global morbidity and mortality","volume":"18","author":"A Afroz","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"pgph.0004281.ref034","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.70135","article-title":"Treatment response and clinical features of snakebite envenomation in Alborz province, Iran: A cross-sectional study","volume":"7","author":"H Farajidana","year":"2024","journal-title":"Health Sci Rep"},{"issue":"3","key":"pgph.0004281.ref035","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4269\/ajtmh.1997.56.291","article-title":"First clinical experiences with a new ovine Fab Echis ocellatus snake bite antivenom in Nigeria: randomized comparative trial with Institute Pasteur Serum (Ipser) Africa antivenom","volume":"56","author":"WP Meyer","year":"1997","journal-title":"Am J Trop Med Hyg"},{"issue":"5942","key":"pgph.0004281.ref036","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/bmj.4.5942.437","article-title":"Bites by the saw-scaled or carpet viper (Echis carinatus): trial of two specific antivenoms","volume":"4","author":"DA Warrell","year":"1974","journal-title":"Br Med J"},{"issue":"6","key":"pgph.0004281.ref037","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030150","article-title":"Confronting the neglected problem of snake bite envenoming: the need for a global partnership","volume":"3","author":"JM Guti\u00e9rrez","year":"2006","journal-title":"PLoS Med"},{"issue":"3","key":"pgph.0004281.ref038","first-page":"277","article-title":"Snake antivenoms","volume":"41","author":"DG Lalloo","year":"2003","journal-title":"Journal of Toxicology: Clinical Toxicology"},{"issue":"22","key":"pgph.0004281.ref039","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJM198411293112204","article-title":"A prospective clinical and immunologic analysis of patients with serum sickness","volume":"311","author":"TJ Lawley","year":"1984","journal-title":"N Engl J Med"},{"issue":"10","key":"pgph.0004281.ref040","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3390\/toxins14100694","article-title":"Early Adverse Reactions to Snake Antivenom: Poison Center Data Analysis","volume":"14","author":"C Sriapha","year":"2022","journal-title":"Toxins (Basel)"},{"issue":"3","key":"pgph.0004281.ref041","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1080\/15563650.2025.2449938","article-title":"Safety profile of antivenom in a cohort of patients envenomed by Deinagkistrodon acutus in Hangzhou, Zhejiang Province, Southeast China","volume":"63","author":"M Tu","year":"2025","journal-title":"Clin Toxicol (Phila)"},{"issue":"6","key":"pgph.0004281.ref042","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/82691","article-title":"Clemens Freiherr von Pirquet: explaining immune complex disease in 1906","volume":"1","author":"AM Silverstein","year":"2000","journal-title":"Nat Immunol"},{"issue":"1","key":"pgph.0004281.ref043","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0196-0644(97)70111-2","article-title":"Successful treatment of crotalid-induced neurotoxicity with a new polyspecific crotalid Fab antivenom","volume":"30","author":"RF Clark","year":"1997","journal-title":"Ann Emerg Med"},{"issue":"1","key":"pgph.0004281.ref044","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000603","article-title":"Snake bite in South Asia: a review","volume":"4","author":"E Alirol","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pgph.0004281.ref045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004325","article-title":"Development of equine IgG antivenoms against major snake groups in Mozambique","volume":"10","author":"FR Guidolin","year":"2016","journal-title":"PLOS Neglected Tropical Diseases"},{"issue":"1","key":"pgph.0004281.ref046","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/15563650.2015.1101771","article-title":"Incidence of serum sickness after the administration of Australian snake antivenom (ASP-22)","volume":"54","author":"NM Ryan","year":"2016","journal-title":"Clin Toxicol (Phila)"},{"issue":"1","key":"pgph.0004281.ref047","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0196-0644(97)70107-0","article-title":"Affinity-purified, mixed monospecific crotalid antivenom ovine Fab for the treatment of crotalid venom poisoning","volume":"30","author":"RC Dart","year":"1997","journal-title":"Ann Emerg Med"},{"issue":"16","key":"pgph.0004281.ref048","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1001\/archinte.161.16.2030","article-title":"A randomized multicenter trial of crotalinae polyvalent immune Fab (ovine) antivenom for the treatment for crotaline snakebite in the United States","volume":"161","author":"RC Dart","year":"2001","journal-title":"Arch Intern Med"},{"key":"pgph.0004281.ref049","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-227X-11-2","article-title":"Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop","volume":"11","author":"EJ Lavonas","year":"2011","journal-title":"BMC Emerg Med"},{"issue":"7","key":"pgph.0004281.ref050","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/qjmed\/hcn048","article-title":"A randomised controlled trial of intramuscular vs. intravenous antivenom for latrodectism--the RAVE study","volume":"101","author":"GK Isbister","year":"2008","journal-title":"QJM"},{"issue":"3","key":"pgph.0004281.ref051","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4269\/ajtmh.2007.77.538","article-title":"Clinical trial of an F(ab\u2019)2 polyvalent equine antivenom for African snake bites in Benin","volume":"77","author":"Investigators of African Antivipmyn in Benin.","year":"2007","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"pgph.0004281.ref052","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.toxicon.2011.11.017","article-title":"Comparative study of the efficacy and safety of two polyvalent, caprylic acid fractionated [IgG and F(ab\u2019)2] antivenoms, in Bothrops asper bites in Colombia","volume":"59","author":"R Otero-Pati\u00f1o","year":"2012","journal-title":"Toxicon"},{"issue":"10148","key":"pgph.0004281.ref053","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0140-6736(18)31224-8","article-title":"Vulnerability to snakebite envenoming: a global mapping of hotspots","volume":"392","author":"J Longbottom","year":"2018","journal-title":"Lancet"},{"key":"pgph.0004281.ref054","volume-title":"A strategy for prevention and control","author":"WS Envenoming","year":"2019"},{"issue":"2","key":"pgph.0004281.ref055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007059","article-title":"Strategy for a globally coordinated response to a priority neglected tropical disease: Snakebite envenoming","volume":"13","author":"DJ Williams","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"pgph.0004281.ref056","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.toxicon.2009.11.020","article-title":"Snakebite envenoming from a global perspective: Towards an integrated approach","volume":"56","author":"JM Guti\u00e9rrez","year":"2010","journal-title":"Toxicon"},{"issue":"5","key":"pgph.0004281.ref057","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMra013477","article-title":"Bites of venomous snakes","volume":"347","author":"BS Gold","year":"2002","journal-title":"N Engl J Med"},{"issue":"5","key":"pgph.0004281.ref058","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/j.1875-9114.2012.01026.x","article-title":"Safety and cost-effectiveness of a clinical protocol implemented to standardize the use of Crotalidae polyvalent immune Fab antivenom at an academic medical center","volume":"32","author":"KA Weant","year":"2012","journal-title":"Pharmacotherapy"}],"container-title":["PLOS Global Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0004281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T18:24:07Z","timestamp":1764008647000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0004281"}},"subtitle":[],"editor":[{"given":"Muhammed O","family":"Afolabi","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":58,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pgph.0004281","relation":{},"ISSN":["2767-3375"],"issn-type":[{"value":"2767-3375","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]}}}